As of 2025-06-02, the EV/EBITDA ratio of Bridge Biotherapeutics Inc (288330.KQ) is -1.94. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 288330.KQ's latest enterprise value is 35,039.39 mil KRW. 288330.KQ's TTM EBITDA according to its financial statements is -18,069.47 mil KRW. Dividing these 2 quantities gives us the above 288330.KQ EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.1x - 21.5x | 16.3x |
| Forward P/E multiples | 13.1x - 24.0x | 18.6x |
| Fair Price | (4,482.86) - (7,370.38) | (5,973.36) |
| Upside | -713.3% - -1108.3% | -917.1% |
| Date | EV/EBITDA |
| 2025-05-02 | -2.35 |
| 2025-04-30 | -2.41 |
| 2025-04-29 | -2.90 |
| 2025-04-28 | -2.97 |
| 2025-04-25 | -3.12 |
| 2025-04-24 | -3.24 |
| 2025-04-23 | -3.46 |
| 2025-04-22 | -3.48 |
| 2025-04-21 | -4.20 |
| 2025-04-18 | -6.07 |
| 2025-04-17 | -8.72 |
| 2025-04-16 | -12.54 |
| 2025-04-15 | -17.97 |
| 2025-04-14 | -25.71 |
| 2025-04-11 | -25.68 |
| 2025-04-10 | -22.96 |
| 2025-04-09 | -21.58 |
| 2025-04-08 | -22.93 |
| 2025-04-07 | -21.95 |
| 2025-04-04 | -21.52 |
| 2025-04-03 | -22.15 |
| 2025-04-02 | -22.15 |
| 2025-04-01 | -22.07 |
| 2025-03-31 | -22.36 |
| 2025-03-28 | -22.93 |
| 2025-03-27 | -23.60 |
| 2025-03-26 | -21.43 |
| 2025-03-25 | -20.62 |
| 2025-03-24 | -21.43 |
| 2025-03-21 | -17.39 |
| 2025-03-20 | -17.45 |
| 2025-03-19 | -18.17 |
| 2025-03-18 | -18.80 |
| 2025-03-17 | -18.80 |
| 2025-03-14 | -18.80 |
| 2025-03-13 | -17.74 |
| 2025-03-12 | -17.50 |
| 2025-03-11 | -16.03 |
| 2025-03-10 | -14.30 |
| 2025-03-07 | -14.36 |
| 2025-03-06 | -14.25 |
| 2025-03-05 | -14.15 |
| 2025-03-04 | -13.85 |
| 2025-02-28 | -13.75 |
| 2025-02-27 | -14.27 |
| 2025-02-26 | -13.37 |
| 2025-02-25 | -13.11 |
| 2025-02-24 | -13.45 |
| 2025-02-21 | -14.33 |
| 2025-02-20 | -12.62 |